SAN

82.86

+0.08%↑

UCB

267.9

+3.32%↑

SHL.DE

36.38

+0.61%↑

ARGX

643

+3.71%↑

VIE

33.23

+1.75%↑

SAN

82.86

+0.08%↑

UCB

267.9

+3.32%↑

SHL.DE

36.38

+0.61%↑

ARGX

643

+3.71%↑

VIE

33.23

+1.75%↑

SAN

82.86

+0.08%↑

UCB

267.9

+3.32%↑

SHL.DE

36.38

+0.61%↑

ARGX

643

+3.71%↑

VIE

33.23

+1.75%↑

SAN

82.86

+0.08%↑

UCB

267.9

+3.32%↑

SHL.DE

36.38

+0.61%↑

ARGX

643

+3.71%↑

VIE

33.23

+1.75%↑

SAN

82.86

+0.08%↑

UCB

267.9

+3.32%↑

SHL.DE

36.38

+0.61%↑

ARGX

643

+3.71%↑

VIE

33.23

+1.75%↑

Search

ICADE.

Fechado

SetorSaúde

19.82 2.43

Visão Geral

Variação de preço das ações

24h

Atual

Mín

19.34

Máximo

19.9

Indicadores-chave

By Trading Economics

Rendimento

60M

-31M

Vendas

84M

707M

EPS

-0.41

Margem de lucro

-4.427

Funcionários

983

EBITDA

-152M

-14M

Recomendações

By TipRanks

Recomendações

Venda Forte

Previsão para 12 meses

+3.99% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-115M

1.5B

Abertura anterior

17.39

Fecho anterior

19.82

Sentimento de Notícias

By Acuity

50%

50%

148 / 349 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

ICADE. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

31 de mar. de 2026, 23:31 UTC

Ações em Alta

Stocks to Watch: Nike, RH, NCino

31 de mar. de 2026, 22:35 UTC

Ganhos

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 de abr. de 2026, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 de mar. de 2026, 23:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 de mar. de 2026, 23:43 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 de mar. de 2026, 23:33 UTC

Conversa de Mercado
Notícias Principais

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 de mar. de 2026, 23:21 UTC

Ganhos

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 de mar. de 2026, 23:14 UTC

Conversa de Mercado
Ganhos

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 de mar. de 2026, 23:12 UTC

Conversa de Mercado

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke 2025 Loss Widens >000002.SZ

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 de mar. de 2026, 21:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 de mar. de 2026, 21:36 UTC

Conversa de Mercado

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 de mar. de 2026, 21:35 UTC

Ganhos

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 de mar. de 2026, 21:35 UTC

Ganhos

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 de mar. de 2026, 21:35 UTC

Ganhos

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 de mar. de 2026, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 de mar. de 2026, 21:33 UTC

Ganhos

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 de mar. de 2026, 21:32 UTC

Ganhos

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 de mar. de 2026, 21:28 UTC

Ganhos

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 de mar. de 2026, 21:26 UTC

Ganhos

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 de mar. de 2026, 21:25 UTC

Ganhos

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 de mar. de 2026, 21:24 UTC

Conversa de Mercado
Ganhos

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 de mar. de 2026, 21:22 UTC

Ganhos

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 de mar. de 2026, 21:22 UTC

Ganhos

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 de mar. de 2026, 21:21 UTC

Ganhos

Nike's Digital Channel Still Too Promotional, CFO Says

31 de mar. de 2026, 21:20 UTC

Ganhos

Nike CEO: Converse Remains Important to Portfolio

Comparação entre Pares

Variação de preço

ICADE. Previsão

Preço-alvo

By TipRanks

3.99% parte superior

Previsão para 12 meses

Média 19.82 EUR  3.99%

Máximo 25 EUR

Mínimo 17.1 EUR

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para ICADE. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Venda Forte

5 ratings

0

Comprar

1

Manter

4

Vender

Pontuação Técnica

By Trading Central

21.04 / 21.4Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

148 / 349 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre ICADE.

Icade is a full-service real estate company with expertise in both commercial property investment (portfolio worth "6.8bn on a full consolidation basis as of 12/31/2023) and property development (2023 economic revenue of "1.3bn) that operates throughout France. Icade has forged longterm partnerships to respond to emerging trends in the industry. It has made climate issues and the preservation of biodiversity central to its business model to reinvent real estate and contribute to more sustainable cities. It is listed as a "SIIC" on Euronext Paris and its leading shareholder is the Caisse des Dépôts group.
help-icon Live chat